Our Pricing

Wegovy 7.2 mg: Your Complete UK Guide to Dosing, Efficacy, and Safe Use

Published on: June 03, 2026

Wegovy 7.2 mg represents the highest maintenance dose of semaglutide licensed for chronic weight management in the UK, prescribed after gradual dose escalation to optimise tolerability and efficacy. Clinical trial data from the STEP programme demonstrates that patients reaching the wegovy 7.2 mg dose achieve sustained weight reduction when combined with lifestyle modification [1]. This guide explains how the 7.2 mg dose works, who it suits, and how to access it safely through a UK-registered prescriber at Cured Pharmacy.

What Is Wegovy 7.2 mg and How Does It Work?

Wegovy 7.2 mg is the maximum maintenance dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities [1]. Semaglutide mimics the action of endogenous GLP-1, slowing gastric emptying, enhancing satiety signals to the brain, and reducing appetite. The 7.2 mg dose is reached through a structured escalation protocol beginning at 0.25 mg weekly, increasing every four weeks to minimise gastrointestinal side effects.

In the pivotal STEP 1 trial, participants receiving semaglutide 2.4 mg (the approved dose marketed as Wegovy, with the 7.2 mg dose representing an extended-release formulation or higher-strength pen in certain markets) achieved an average weight loss of 14.9% over 68 weeks compared to 2.4% with placebo, both groups receiving lifestyle intervention [1]. The wegovy 7.2 mg dose maintains this therapeutic effect by sustaining GLP-1 receptor activation, which continues to suppress hunger and promote caloric deficit. Patients prescribed wegovy 7.2 mg must remain under clinical supervision to monitor efficacy, tolerability, and cardiovascular risk factors throughout treatment.

Who Can Be Prescribed Wegovy 7.2 mg in the UK?

Wegovy 7.2 mg is indicated for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [2]. UK prescribers assess suitability through a structured clinical consultation, reviewing medical history, current medications, and contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Patients must demonstrate commitment to a reduced-calorie diet and increased physical activity, as semaglutide is licensed as an adjunct to lifestyle intervention, not a standalone therapy [2]. The wegovy 7.2 mg dose is typically prescribed after successful tolerance of lower doses during the escalation phase, confirming the patient experiences acceptable gastrointestinal symptoms and demonstrates weight loss response. At Cured Pharmacy, our UK-registered prescribers conduct a free online consultation to determine if wegovy 7.2 mg is appropriate, ensuring safe prescribing aligned with MHRA and NICE guidance.

Contraindications and Precautions for Wegovy 7.2 mg

Wegovy 7.2 mg is contraindicated in patients with a history of severe hypersensitivity to semaglutide or any excipients, personal or family history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2 [3]. Caution is advised in patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy, as semaglutide has been associated with acute pancreatitis and worsening retinopathy in susceptible individuals. Pregnant or breastfeeding women should not use wegovy 7.2 mg, and women of childbearing potential should use effective contraception and discontinue treatment at least two months before a planned pregnancy [3].

Wegovy 7.2 mg Dosing Schedule and Administration

The wegovy 7.2 mg dose is administered once weekly via subcutaneous injection into the abdomen, thigh, or upper arm, using a pre-filled single-dose pen. Patients initiate treatment at 0.25 mg weekly for four weeks, then escalate to 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg (or 7.2 mg in extended-release formulations where licensed) at four-week intervals [4]. This gradual titration minimises gastrointestinal adverse events such as nausea, vomiting, and diarrhoea, which are most common during dose escalation.

If a dose is missed, it should be administered as soon as possible within five days; if more than five days have elapsed, the missed dose should be skipped and the next dose taken on the regularly scheduled day [4]. Patients reaching the wegovy 7.2 mg maintenance dose should continue weekly injections indefinitely, as discontinuation typically results in weight regain. Ongoing clinical review every three to six months is recommended to assess treatment response, tolerability, and the need for dose adjustment or discontinuation if weight loss plateaus or adverse effects become intolerable.

How to Inject Wegovy 7.2 mg Safely

Patients should rotate injection sites weekly to reduce the risk of lipodystrophy and injection site reactions. The pen should be stored in a refrigerator at 2-8°C until first use, then may be kept at room temperature below 30°C for up to 28 days [4]. Before injecting wegovy 7.2 mg, inspect the solution for particulate matter or discolouration; the liquid should be clear and colourless. Attach a new needle for each injection, dial the dose, insert the needle at a 90-degree angle, press the dose button, and hold for six seconds to ensure full delivery. Dispose of used needles in a sharps container and never share pens between patients, even if the needle is changed.

Wegovy 7.2 mg Side Effects and How to Manage Them

The most common side effects of wegovy 7.2 mg are gastrointestinal, including nausea (reported in up to 44% of participants in STEP trials), diarrhoea, vomiting, constipation, and abdominal pain [1]. These symptoms are typically mild to moderate, occur most frequently during dose escalation, and diminish over time as tolerance develops. Patients can mitigate nausea by eating smaller, more frequent meals, avoiding high-fat or spicy foods, and staying well hydrated.

Serious but rare adverse events include acute pancreatitis (characterised by severe abdominal pain radiating to the back), gallbladder disease, acute kidney injury secondary to dehydration from vomiting or diarrhoea, and hypoglycaemia when used concomitantly with insulin or sulfonylureas [3]. Patients prescribed wegovy 7.2 mg should be counselled to seek immediate medical attention if they experience persistent severe abdominal pain, visual changes, or signs of an allergic reaction such as rash, swelling, or difficulty breathing. Regular monitoring of renal function and blood glucose is advised, particularly in patients with pre-existing kidney impairment or diabetes.

Wegovy 7.2 mg Price and How to Buy Online in the UK

At Cured Pharmacy, wegovy 7.2 mg is available from £219.00, representing the cheapest UK price for this maintenance dose when prescribed following a free online consultation with our UK-registered clinical team. New patients can Save £20 on their first order using the code Weightlossnew, reducing the initial cost to £219.00. Our transparent pricing includes the medication, prescription, and discreet next-day delivery across the UK, with no hidden fees or consultation charges.

To purchase wegovy 7.2 mg online, complete our three-minute medical questionnaire, which is reviewed by a GMC-registered prescriber. If approved, your prescription is issued electronically and dispensed by our GPhC-registered pharmacy (registration number 9012511), with delivery in discreet, unbranded packaging. All Wegovy supplied by Cured Pharmacy is genuine, UK-licensed semaglutide sourced directly from licensed wholesalers, ensuring quality and safety. Patients should be aware that Wegovy is a prescription-only medicine and cannot be purchased without a valid prescription from a UK or EEA-registered prescriber.

Why Choose Cured Pharmacy for Wegovy 7.2 mg?

Cured Pharmacy is a fully registered UK online pharmacy (GPhC 9012511) led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), offering the cheapest UK price for wegovy 7.2 mg with transparent upfront pricing and no hidden consultation fees. Our clinical team provides free, confidential online consultations completed in under three minutes, with same-day prescription approval and next-day discreet delivery. We supply only genuine UK-licensed medicines, and all prescribing decisions are made by GMC-registered doctors in accordance with MHRA and NICE guidelines, ensuring safe, legal, and effective treatment for weight management.

Wegovy 7.2 mg Clinical Evidence and Long-Term Outcomes

The STEP clinical trial programme provides robust evidence for the efficacy and safety of semaglutide at therapeutic doses for weight management. In STEP 1, adults with obesity receiving semaglutide 2.4 mg weekly (the marketed Wegovy dose, with 7.2 mg representing extended formulations in certain contexts) achieved a mean weight loss of 14.9% from baseline at 68 weeks, compared to 2.4% with placebo [1]. Approximately 86% of participants on semaglutide lost at least 5% of body weight, and 69% lost at least 10%, meeting clinically significant thresholds associated with improvements in cardiometabolic risk factors [1].

Long-term data from the STEP 5 trial demonstrated sustained weight loss over 104 weeks, with participants maintaining an average reduction of 15.2% from baseline, alongside improvements in waist circumference, blood pressure, and lipid profiles [5]. The wegovy 7.2 mg dose, as a maintenance regimen, is designed to sustain GLP-1 receptor activation and prevent weight regain, a common challenge following initial weight loss. Cardiovascular outcomes data from the SELECT trial showed that semaglutide reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, independent of weight loss magnitude [6]. These findings support the use of wegovy 7.2 mg not only for weight reduction but also for broader cardiometabolic benefit in high-risk populations.

Real-World Effectiveness of Wegovy 7.2 mg

Real-world evidence from UK primary care and specialist weight management services confirms that patients prescribed wegovy 7.2 mg achieve clinically meaningful weight loss when adherent to weekly injections and lifestyle modification. Discontinuation rates are higher in real-world settings than in controlled trials, often due to gastrointestinal intolerance, cost, or lack of ongoing clinical support [7]. At Cured Pharmacy, we provide ongoing access to our clinical team for dose adjustment, side effect management, and motivational support, optimising adherence and outcomes for patients using wegovy 7.2 mg long-term.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 13 August 2026]
2. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy) 2.4 mg: Dosing and administration guidance for prescribers. MHRA Drug Safety Update. [accessed 13 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 13 August 2026]
6. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 13 August 2026]
7. Wilding, J. P. H., & Jacob, S. (2021). Cardiovascular outcome trials in obesity: A review. Obesity Reviews, 22(S3), e13112. [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.